Objective To evaluate the clinical curative effect of the ginseng and astragalus hypoglycemic granule in the treatment of patients with impaired glucose tolerance. Methods 90 cases of patients with impaired glucose tolerance were chosen in our hospital from June 2014 to June 2016, randomly divided into control group and treatment group,45 cases each. Two groups of patients were given lifestyle intervention,diet control,and treatment of the relevant basic diseases such as antihypertensive,lipid,etc. Control group of patients was given oral metformin hydrochloride. With dinner,0.5 g each time,3 times a day. Treatment group of patients was given oral ginseng and astragalus hypoglycemic granule,3 g at a time,three times a day. One month for a period of treatment,two groups of patients were three courses of treatment. Observation of two groups were observed before and after treatment in both groups fasting blood glucose(FBG),blood glucose 2 hours after meal(2 HPG),glycosylated hemoglobin(HbA1c), fasting insulin(FINS),insulin of 2 hours after meal(2 hins),body mass index(BMI),total cholesterol(TC),triglyceride(TG),clinical curative effect,and the occurrence of adverse reactions were recorded. Results No obvious difference was found between the indicators In the two groups of patients before treatment. After treatment,the indicators were better than that of the control group and treatment group before the treatment (P<0.05),index change degree between the observation group and control group was no statistically significant(P>0.05). Incidence of adverse reactions in observation group was lower than control group's(P<0.05). Conclusion Ginseng and astragalus hypoglycemic granule can treat patients with impaired glucose tolerance,has similar clinical effection to metformin hydrochloride and significantly lower adverse reaction. Ginseng and astragalus hypoglycemic granule has good security,can be chosen for patients who can not tolerance adverse reactions of metformin hydrochloride.%目的 评价参芪降糖颗粒治疗糖耐量异常患者的临床疗效.方法 选择2014年6月至2016年6月治疗的糖耐量异常患者90例,随机分为对照组和观察组,每组各45例.两组患者均给予生活方式干预,饮食控制,并治疗相关基础病如降压、调脂等.对照组患者口服二甲双胍.随餐服,0.5g/次,3次/d.观察组患者口服参芪降糖颗粒,3g/次,3次/d.1个月为1个疗程,两组患者均治疗3个疗程.观察两组患者治疗前后空腹血糖(FBG),餐后2h血糖(2hPG),糖化血红蛋白(HbA1c),空腹胰岛素(FINS),餐后2h胰岛素(2hinS),体质量指数(BMI),总胆固醇(TC),甘油三酯(TG),临床疗效,并记录不良反应的发生情况.结果 治疗前两组患者各项指标无明显差异.治疗后,两组组内各项指标比较均优于治疗前,差异有统计学意义(P<0.05);两组组间指标比较无明显差异(P>0.05).两组患者不良反应发生率差异具有统计学意义(P<0.05).结论 参芪降糖颗粒治疗糖耐量异常患者的疗效与二甲双胍相当,且具有临床不良反应发生率低的优势,安全性好,对不能耐受二甲双胍的患者是可选择的临床替代药物.
展开▼
